Table 3.

Observed recovery and all-cause mortality proportions at 60 days, by agent and concurrent controls, modified intention-to-treat population.

Agent	Recovered	Died
Apremilast (n = 67)	34 (51%)	22 (33%)
Apremilast Controls (n = 143)	80 (56%)	45 (31%)
Cenicriviroc (n = 92)	52 (57%)	38 (41%)
Cenicriviroc controls (n = 169)	95 (56%)	56 (33%)
Icatibant (n = 96)	49 (51%)	35 (36%)
Icatibant controls (n = 183)	102 (56%)	62 (34%)
IC14 (n = 67)	36 (54%)	19 (28%)
IC14 controls (n = 76)	48 (63%)	25 (33%)
Celecoxib/famotidine (n = 30)	15 (50%)	12 (40%)
Celecoxib/famotidine controls (n = 37)	29 (78%)	8 (22%)
Dornase (n = 39)	22 (56%)	15 (38%)
Dornase controls (n = 88)	55 (62%)	31 (35%)

Note that controls may appear in more than one row if they were concurrent to multiple agents.